{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T03:01:58Z","timestamp":1789786918147,"version":"4.0.1"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006190","name":"Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006190","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.jpba.2026.117696","type":"journal-article","created":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T14:03:41Z","timestamp":1786284221000},"page":"117696","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Identification and quantitation strategies of circulating cysteine-conjugated linker-payload catabolites and free payload from a cleavable-linker ADC"],"prefix":"10.1016","volume":"282","author":[{"given":"Hermes","family":"Licea-Perez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9191-4618","authenticated-orcid":false,"given":"Kasie","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5474-5890","authenticated-orcid":false,"given":"Kevin","family":"Colizza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2026.117696_bib1","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Sig. Transduct. Target. Ther."},{"key":"10.1016\/j.jpba.2026.117696_bib2","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1158\/2159-8290.CD-24-0708","article-title":"The journey of antibody-drug conjugates: lessons learned from 40 years of development","volume":"14","author":"Colombo","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.jpba.2026.117696_bib3","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.drup.2014.11.001","article-title":"Antibody-targeted drugs and drug resistance--challenges and solutions","volume":"18","author":"Shefet-Carasso","year":"2015","journal-title":"Drug. Resist. Updat."},{"key":"10.1016\/j.jpba.2026.117696_bib4","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.yrtph.2015.01.014","article-title":"An FDA oncology analysis of antibody-drug conjugates","volume":"71","author":"Saber","year":"2015","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.jpba.2026.117696_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2019.104429","article-title":"An FDA oncology analysis of toxicities associated with PBD-containing antibody-drug conjugates","volume":"107","author":"Saber","year":"2019","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.jpba.2026.117696_bib6","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1016\/j.apsb.2021.03.042","article-title":"Antibody\u2013drug conjugates: recent advances in linker chemistry","volume":"11","author":"Su","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.jpba.2026.117696_bib7","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1007\/s11095-014-1584-z","article-title":"Preclinical pharmacokinetic considerations for the development of antibody drug conjugates","volume":"32","author":"Kamath","year":"2015","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jpba.2026.117696_bib8","doi-asserted-by":"crossref","first-page":"201","DOI":"10.4155\/bio.12.299","article-title":"Bioanalytical assay strategies for the development of antibody\u2013drug conjugate biotherapeutics","volume":"5","author":"Kaur","year":"2013","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jpba.2026.117696_bib9","doi-asserted-by":"crossref","first-page":"4979","DOI":"10.1021\/acs.analchem.6b00976","article-title":"Where did the linker-payload go? A quantitative investigation on the destination of the released linker-payload from an antibody-drug conjugate with a maleimide linker in plasma","volume":"88","author":"Wei","year":"2016","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jpba.2026.117696_bib10","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/nbt.2108","article-title":"Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates","volume":"30","author":"Shen","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jpba.2026.117696_bib11","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3390\/ijms17040561","article-title":"Linkers having a crucial role in antibody-drug conjugates","volume":"17","author":"Lu","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jpba.2026.117696_bib12","doi-asserted-by":"crossref","first-page":"713","DOI":"10.3390\/cancers15030713","article-title":"Mechanisms of ADC toxicity and strategies to increase ADC tolerability","volume":"15","author":"Nguyen","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.jpba.2026.117696_bib13","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.4155\/bio-2021-0171","article-title":"Overcoming challenges associated with the bioanalysis of cysteine-conjugated metabolites in the presence of antibody-drug conjugates","volume":"13","author":"Mayer","year":"2021","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jpba.2026.117696_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2025.117105","article-title":"Strategies for accurate quantitation of free payloads in antibody-drug-conjugates: application for a payload with a labile lactone group","volume":"266","author":"Fang","year":"2025","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2026.117696_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2025.116964","article-title":"LBA and LC-MS\/MS based comprehensive bioanalytical methods for FDA018, a Trop-2 targeted antibody-drug conjugate","volume":"264","author":"Cheng","year":"2025","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2026.117696_bib16","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.jpba.2015.09.015","article-title":"Chemical de-conjugation for investigating the stability of small molecule drugs in antibody-drug conjugates","volume":"117","author":"Chen","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2026.117696_bib17","unstructured":"U.S. Food and Drug Administration, Safety Testing of Drug Metabolites: Guidance for Industry, 2008. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/safety-testing-drug-metabolites (accessed July 21, 2026)."},{"key":"10.1016\/j.jpba.2026.117696_bib18","unstructured":"International Council for Harmonisation (ICH), ICH M3(R2): Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals, 2009. https:\/\/database.ich.org\/sites\/default\/files\/M3-R2-Guideline.pdf (accessed July 21, 2026)."},{"key":"10.1016\/j.jpba.2026.117696_bib19","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.4155\/bio.15.87","article-title":"Bioanalytical approaches for characterizing catabolism of antibody\u2013drug conjugates","volume":"7","author":"Saad","year":"2015","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jpba.2026.117696_bib20","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1124\/dmd.122.001135","article-title":"Detection and characterization of in vitro payload-containing catabolites of noncleavable antibody-drug conjugates by high-resolution mass spectrometry and multiple data mining tools","volume":"51","author":"Cai","year":"2023","journal-title":"Drug. Metab. Dispos."},{"key":"10.1016\/j.jpba.2026.117696_bib21","doi-asserted-by":"crossref","first-page":"997","DOI":"10.4155\/bio.13.38","article-title":"Bioanalysis of antibody\u2013drug conjugates: American Association of Pharmaceutical Scientists Antibody\u2013Drug Conjugate Working Group position paper","volume":"5","author":"Gorovits","year":"2013","journal-title":"Bioanalysis"}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073170852600364X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073170852600364X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T02:32:12Z","timestamp":1789785132000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S073170852600364X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":21,"alternative-id":["S073170852600364X"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2026.117696","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification and quantitation strategies of circulating cysteine-conjugated linker-payload catabolites and free payload from a cleavable-linker ADC","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2026.117696","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117696"}}